Alpha-1 antitrypsin deficiency (AATD ... University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health ...
Krystal Biotech (KRYS) clinical data updates for both KB408 and KB407, the Company’s clinical-stage, inhaled genetic medicine ...
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to ...
alpha-1 AT = alpha-1 antitrypsin; ANA = antinuclear antibodies; SMA = smooth muscle antibodies; anti-LKM1 = antibodies to liver/kidney microsome type 1; AMA = antimitochondrial antibodies ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
CRISPR stocks are high risk but hold potential for aggressive ... $1.8 billion Sickle cell disease, alpha-1 antitrypsin deficiency, glycogen storage disease 1a, T-cell leukemia/lymphoma CRISPR ...
which is being evaluated in a phase 1/2 study for the treatment of patients with Alpha-1 Antitrypsin deficiency [AATD]. Initial results from this early-stage study are expected to be released in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback